Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchAtavistik Bio Unveils Promising Preclinical Data for ATV-1601, a Small Molecule Inhibitor Targeting AKT1 E17K Mutations
Oct 23, 2024
CambridgeBiotechnologySoftwareHealth CareScience And Engineering
Product Description
Atavistik Bio presented preclinical data on ATV-1601, a selective allosteric small molecule inhibitor for AKT1 E17K-driven cancers at the EORTC-NCI-AACR Symposium. The data highlights ATV-1601's enhanced efficacy and improved tolerability compared to existing pan-AKT inhibitors, with plans to commence human trials in early 2025.
Company Information
Company
Atavistik Bio
Location
Cambridge, Massachusetts, United States
About
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery. ATV-1601, a selective allosteric inhibitor for solid tumors, is anticipated to enter the clinic in early 2025. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Atavistik Bio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.